Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Bucur, Octavian ^a,b   Stancu, Andreea Lucia ^a,c   Goganau, Ioana ^a,c   Petrescu, Stefana Maria ^b   Pennarun, Bodvael ^a   Bertomeu, Thierry ^a   Dewar, Rajan ^a   Khosravi Far, Roya ^a,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BCR ABL PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CRK LIKE PROTEIN; DASATINIB; DOCETAXEL; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NILOTINIB; PACLITAXEL; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; VINCRISTINE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BENZAMIDES; BORONIC ACIDS; CASPASES; CELL DEATH; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA; MITOSIS; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; THIAZOLES;

EID: 84885408946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077390     Document Type: Article

References (57)

1. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, et al. (2009) Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res 69(16):: 6546-6555. doi:10.1158/0008-5472.CAN-09-0605. PubMed: 19654305.
2. Jagani Z, Singh A, Khosravi-Far R, (2008) FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 1785(1):: 63-84. PubMed: 17980712.
3. Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, et al. (2013) Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 27(1):: 118-129. doi:10.1038/leu.2012.222. PubMed: 22858987.
4. Dai Y, Rahmani M, Pei XY, Dent P, Grant S, (2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms. Blood 104(2):: 509-518. doi:10.1182/blood-2003-12-4121. PubMed: 15039284.
5. Razzak M, (2013) Haematology: Ponatinib-the next TKI challenge. Nat Rev Clin Oncol 10(2):: 65.
6. Dewar R, Chen ST, Yeckes-Rodin H, Miller K, Khosravi-Far R, (2011) Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker. Cancer Biol Ther 11(6):: 552-558. doi:10.4161/cbt.11.6.14675. PubMed: 21282974.
7. Available: www.clinicaltrials.gov.
8. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, et al. (2011) Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk 11(4):: 355-360. doi:10.1016/j.clml.2011.06.004. PubMed: 21816374.
9. Dai Y, Yu C, Singh V, Tang L, Wang Z, et al. (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61(13):: 5106-5115. PubMed: 11431348.
10. Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, et al. (2011) Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther 10(8):: 1509-1519. doi:10.1158/1535-7163.MCT-10-0944. PubMed: 21680752.
11. Kim SY, Kim DH, Lee HJ, Seo YJ, Lee JH, et al. (2011) Treatment of Disseminated Classic Type of Kaposi's Sarcoma with Paclitaxel. Ann Dermatol 23(4):: 504-507. doi:10.5021/ad.2011.23.4.504. PubMed: 22148021.
12. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, et al. (2003) Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63(9):: 2118-2126. PubMed: 12727828.
13. Ray S, Bucur O, Almasan A, (2005) Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10(6):: 1411-1418. doi:10.1007/s10495-005-2490-y. PubMed: 16215673.
14. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. doi:10.1016/0065-2571(84)90007-4. PubMed: 6382953.
15. Singh A, Ye M, Bucur O, Zhu S, Tanya Santos M, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Cell Biol 21(6):: 1140-1152. doi:10.1091/mbc.E09-09-0795. PubMed: 20110348.
16. Gangemi RM, Santamaria B, Bargellesi A, Cosulich E, Fabbi M, (2000) Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation. Int J Cancer 85(4):: 527-533. doi:10.1002/(SICI)1097-0215(20000215)85:4. PubMed: 10699926.
17. Bucur O, Stancu AL, Khosravi-Far R, Almasan A, (2012) Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death. Drosophila Inf Serv 3: e263.
18. Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, et al. (2010) A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res 70(18):: 7325-7335. doi:10.1158/0008-5472.CAN-10-0607. PubMed: 20807813.
19. Wu J, Meng F, Kong LY, Peng Z, Ying Y, et al. (2008) Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100(13):: 926-939. doi:10.1093/jnci/djn188. PubMed: 18577747.
20. Coppo P, Dusanter-Fourt I, Millot G, Nogueira MM, Dugray A, et al. (2003) Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 22(26):: 4102-4110. doi:10.1038/sj.onc.1206607. PubMed: 12821944.
21. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, et al. (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7(10):: 3169-3175. doi:10.1158/1535-7163.MCT-08-0314. PubMed: 18852120.
22. Wei G, Rafiyath S, Liu D, (2010) First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Hematol Oncol 3: 47. doi:10.1186/1756-8722-3-47.
23. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, et al. (2010) Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 70(4):: 1513-1523. doi:10.1158/0008-5472.CAN-09-2181. PubMed: 20145140.
24. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, et al. (2002) Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 1(13):: 1191-1200. PubMed: 12479700.
25. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, et al. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471(7336):: 110-114. doi:10.1038/nature09779. PubMed: 21368834.
26. Wu J, Meng F, Lu H, Kong L, Bornmann W, et al. (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111(7):: 3821-3829. doi:10.1182/blood-2007-08-109330. PubMed: 18235045.
27. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, et al. (2002) The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99(8):: 2957-2968. doi:10.1182/blood.V99.8.2957. PubMed: 11929787.
28. Ptasznik A, Urbanowska E, Chinta S, Costa MA, Katz BA, et al. (2002) Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 196(5):: 667-678. doi:10.1084/jem.20020519. PubMed: 12208881.
29. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R, (2003) Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U_S_A 100(11):: 6523-6528. doi:10.1073/pnas.0731871100. PubMed: 12750477.
30. Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, et al. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8(3):: 285-293. doi:10.1038/nchembio.775. PubMed: 22286129.
31. Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, et al. (2009) A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLOS ONE 4(10):: e7439. doi:10.1371/journal.pone.0007439. PubMed: 19823681.
32. Sattler M, Salgia R, (1998) Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia 12(5):: 637-644. doi:10.1038/sj.leu.2401010. PubMed: 9593259.
33. Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, et al. (2001) Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res 61(4):: 1398-1405. PubMed: 11245441.
34. Uemura N, Griffin JD, (1999) The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration. J Biol Chem 274(53):: 37525-37532. doi:10.1074/jbc.274.53.37525. PubMed: 10608804.
35. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K, (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101(8):: 3236-3239. doi:10.1182/blood-2002-08-2675. PubMed: 12446442.
36. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, et al. (2002) Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 62(20):: 5761-5769. PubMed: 12384536.
37. Wang Y, Cai D, Brendel C, Barett C, Erben P, et al. (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109(5):: 2147-2155. doi:10.1182/blood-2006-08-040022. PubMed: 17090651.
38. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, et al. (2002) Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99(2):: 664-671. doi:10.1182/blood.V99.2.664. PubMed: 11781252.
39. Yu C, Rahmani M, Conrad D, Subler M, Dent P, et al. (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102(10):: 3765-3774. doi:10.1182/blood-2003-03-0737. PubMed: 12893773.
40. Stein SJ, Baldwin AS, (2011) NF-κB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death. Oncogene 30(45):: 4557-4566. doi:10.1038/onc.2011.156. PubMed: 21625221.
41. Gopalan A, Yu W, Sanders BG, Kline K, (2013) Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett 329(1):: 9-16. doi:10.1016/j.canlet.2012.08.031. PubMed: 22960596.
42. Plati J, Bucur O, Khosravi-Far R, (2008) Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 104(4):: 1124-1149. doi:10.1002/jcb.21707. PubMed: 18459149.
43. Bucur O, Ray S, Bucur MC, Almasan A, (2006) APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11: 1549-1568. doi:10.2741/1903. PubMed: 16368536.
44. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, et al. (2008) Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 615: 47-79. doi:10.1007/978-1-4020-6554-5_4. PubMed: 18437891.
45. Plati J, Bucur O, Khosravi-Far R, (2011) Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 3(4):: 279-296. doi:10.1039/c0ib00144a. PubMed: 21340093.
46. Myssina S, Helgason GV, Serrels A, Jørgensen HG, Bhatia R, et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Exp Hematol 37(2):: 206-214. doi:10.1016/j.exphem.2008.10.013. PubMed: 19100678.
47. Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F, (2012) Novel strategies in the treatment of castration-resistant prostate cancer. Int J Oncol 40(5):: 1313-1320. PubMed: 22322981.
48. Habermann TM, (2012) New developments in the management of diffuse large B-cell lymphoma. Hematology 17 (Suppl 1):: S93-S97. PubMed: 22507791.
49. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325895.htm.
50. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, et al. (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15):: 3403-3412. doi:10.1182/blood-2011-11-390120. PubMed: 22371878.
51. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, et al. (2012) Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120(13):: 2573-2580. doi:10.1182/blood-2012-03-415307. PubMed: 22896000.
52. Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, et al. (2012) Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 26(10):: 2269-2276. doi:10.1038/leu.2012.81. PubMed: 22430634.
53. Podar K, Chauhan D, Anderson KC, (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23(1):: 10-24. doi:10.1038/leu.2008.259. PubMed: 18843284.
54. Correia AL, Bissell MJ, (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Update 15(1-2):: 39-49. doi:10.1016/j.drup.2012.01.006. PubMed: 22335920.
55. Seke Etet PF, Vecchio L, Nwabo Kamdje AH, (2012) Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment. Cell Signal 24(9):: 1883-1888. doi:10.1016/j.cellsig.2012.05.015. PubMed: 22659137.
56. Yusuf RZ, Wang YH, Scadden DT, (2012) The secrets of the bone marrow niche: Metabolic priming for AML. Nat Med 18(6):: 865-867. doi:10.1038/nm.2831. PubMed: 22673998.
57. Nardi V, Naveiras O, Azam M, Daley GQ, (2009) ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood 113(16):: 3813-3820. doi:10.1182/blood-2008-07-167189. PubMed: 19171873.